ledipasvir/sofosbuvir / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 54 Diseases   8 Trials   8 Trials   2662 News 


«12345678910111213...2324»
  • ||||||||||  ledipasvir/sofosbuvir / Generic mfg.
    Trial completion date, Trial primary completion date:  Harvoni Treatment Porphyria Cutanea Tarda (clinicaltrials.gov) -  Jun 2, 2022   
    P2,  N=25, Active, not recruiting, 
    No abstract available Trial completion date: May 2022 --> Sep 2022 | Trial primary completion date: May 2022 --> Sep 2022
  • ||||||||||  Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
    Journal:  Effect of Sofosbuvir/Ledipasvir and Glecaprevir/Pibrentasvir on Serum Creatinine. (Pubmed Central) -  May 12, 2022   
    Treatment of chronic hepatitis C infection with both SOF/LDV and GLE/PIB regimens may result in an increase of creatinine, and 6-7% will have an increase in serum creatinine of ≥0.3 mg/dL. The increase in creatinine, however, is unrelated to the type of DAA combination.
  • ||||||||||  Zepatier (grazoprevir/elbasvir) / Merck (MSD), Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead, Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
    Reported safety of HCV direct-acting antivirals with opioids: 2017 to 2021 (Poster Area) -  May 12, 2022 - Abstract #EASLILC2022EASL_ILC_2232;    
    With the limitations of FAERS data (under or duplicate reporting, inability to establish causation or incidence), these data showthat among ∼58, 000 fentanyl, ∼189, 000 oxycodone, and ∼100, 000 hydrocodone AEs reported to FAERS since 2017, a small proportion (0.19%) have been reported in association with concomitant DAA therapy, with no association between recorded events and a specific DAA regimen. This should reassure HCV treaters on a lack of safety signal for concomitant opioid and DAA use.
  • ||||||||||  Zepatier (grazoprevir/elbasvir) / Merck (MSD), Daklinza (daclatasvir) / BMS, Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
    Eliminating hepatitis C virus infection in prisons: 7 years of experience (Poster Area) -  May 12, 2022 - Abstract #EASLILC2022EASL_ILC_1941;    
    All the 79 patients were initially treated with Sofosbuvir/Ledipasvir and Daclatasvir with or without ribavirin (according to criteria defined in initial protocols) and more recently, Grazoprevir/Elbasvir and pangenotypic drugs, namely Sofosbuvir/Velpatasvir, and Glecaprevir/Pibrentasvir. Our encouraging data is a result from an optimized partnership between the healthcare team in prisons and our hospital, allowing a fast diagnosis, an agile disease staging and adequate treatment, minimizing future risk of transmission and taking us closer to eliminating the infection by 2030.
  • ||||||||||  ledipasvir/sofosbuvir / Generic mfg.
    Clinical, Journal:  Non-adherence to LDV/SOF did not predict SVR in a randomized controlled trial of HIV/HCV coinfected persons who use drugs. (Pubmed Central) -  May 11, 2022   
    Our encouraging data is a result from an optimized partnership between the healthcare team in prisons and our hospital, allowing a fast diagnosis, an agile disease staging and adequate treatment, minimizing future risk of transmission and taking us closer to eliminating the infection by 2030. Treatment persistence led to high SVR rates among persons with HIV/HCV, despite imperfect adherence and SUDs.
  • ||||||||||  efavirenz/emtricitabine/tenofovir disoproxil fumarate / Generic mfg., emtricitabine/tenofovir disoproxil fumarate / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
    Journal:  The making of the one pill-Developing single tablet regimens for HIV and for HCV. (Pubmed Central) -  May 9, 2022   
    A fixed-dose combination of ledipasvir and sofosbuvir was developed and approved in 2014 to be the first complete daily single tablet regimen for CHC genotype 1 infection. A spray-drying process for particle morphology engineering in a polymer matrix was used for improving bioavailability.
  • ||||||||||  ledipasvir/sofosbuvir / Generic mfg.
    Clinical, Journal:  Influence of drug-drug interactions on effectiveness and safety of direct-acting antivirals against hepatitis C virus. (Pubmed Central) -  Apr 2, 2022   
    Drug-drug interactions are frequent among hepatitis C-infected patients receiving treatment with direct-acting antivirals. However, the collaboration between physicians and clinical pharmacists makes it possible to detect, evaluate, avoid or clinically manage these drug-drug interactions, in order to maintain whole treatment therapeutic safety and the effectiveness of direct-acting antivirals.
  • ||||||||||  ledipasvir/sofosbuvir / Generic mfg.
    Clinical, Journal, HEOR:  Factors associated with a reduction in the quality of life of patients with chronic hepatitis C treated by ledipasvir/sofosbuvir therapy. (Pubmed Central) -  Apr 2, 2022   
    However, the collaboration between physicians and clinical pharmacists makes it possible to detect, evaluate, avoid or clinically manage these drug-drug interactions, in order to maintain whole treatment therapeutic safety and the effectiveness of direct-acting antivirals. An increase in the baseline level of alanine aminotransferase was found to play a role in the reduction in the quality of life of patients with chronic hepatitis C who had undergone ledipasvir/sofosbuvir therapy.
  • ||||||||||  ribavirin / Generic mfg.
    Clinical, Journal:  The use of antiviral drugs in children. (Pubmed Central) -  Mar 25, 2022   
    Some drugs are used to treat congenital infections, such as valganciclovir and ganciclovir in congenital cytomegalovirus infection...Treatment with direct antiviral agents against hepatitis C virus is approved for children over the age of three; it consists in different therapeutic regimens chosen on the basis of the viral genotype (ledipasvir/sofosbuvir for genotypes 1, 4, 5 and 6, sofosbuvir/ribavirin for genotypes 2 and 3, sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for all genotypes) and it has dramatically changed the course of the illness. Many molecules have been studied in order to treat SARS-CoV-2 infection, but only remdesivir seems to play a role in shortening recovery time, although inclusion criteria are very specific and data on the use in children is limited.
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
    Treatment of hepatitis C in primary healthcare in the country of Georgia (Meeting Point 1) -  Mar 16, 2022 - Abstract #EASLILC2022EASL_ILC_1409;    
    Our study reported the effectiveness of a simplified HCV treatment model in PHCs. Expanding this integrated decentralized model of HCV treatment nationwide would provide an opportunity to improve linkage to care and close gaps in the HCV cascade of care.
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg.
    Real-life effectiveness and safety of sofosbuvir/velpatasvir in difficult to treat hepatitis C patients (Poster Area) -  Mar 16, 2022 - Abstract #EASLILC2022EASL_ILC_1401;    
    70.3% have failed prior DAA treatment (Daclatasvir + asunaprevir n = 16, sofosbuvir+ribavirin n = 3, sofosbuvir + ledipasvir n = 2, glencaprevir+ pibrentasvir n = 3, boceprevir n = 1) Naïve patients received SOF/VEL for 12 weeks and the patientswith prior DAA failure received SOF/VEL for 24 weeks, ribavirin was added in 78.4% of treatment schedules. SOF/VEL is an effective and safe retreatment for difficult to treat HCV population in a real-life setting.
  • ||||||||||  Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
    Treating children with HCV close to home through a virtual national multidisciplinary network (Poster Area) -  Mar 16, 2022 - Abstract #EASLILC2022EASL_ILC_1345;    
    DAA therapy prescribed: Harvoni (21); Epclusa (11); Maviret (2). The National HCV pMDT ODN delivers high quality treatment & equity of access for children & young people, 3–18 yrs with HCV in England, ensuring they receive care close to home with 100% cure rates.
  • ||||||||||  ledipasvir/sofosbuvir / Generic mfg.
    Harvoni = hard boney (Twitter) -  Mar 9, 2022   
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
    Uptake and Utilization Trends of Direct-Acting Antivirals (DAA) for Hepatitis-C in Manitoba, Canada between 1999 and 2019 (In-person & Virtual) -  Mar 8, 2022 - Abstract #ISPOR2022ISPOR_927;    
    CONCLUSIONS : After their introduction, a rapid uptake of newer DAAs was observed in Manitoba and by the end of 2019 DAAs had taken the entire market of HCV medications. Although uptake of DAAs in Manitoba was enthusiastic, efforts are needed to further increase DAA use in order to achieve the goal of HCV elimination.